pharma · Metastatic Prostate Cancer · Prostate Cancer · TLX
Telix Innovations
Telix Innovations clinical programs — 8 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Rue de Hermée 255, Herstal, Région wallonne 4040, BE
- Founded
- 2015
- Employees
- 14
- Programs
- 27
- Drugs
- 11
- Patents
- 3
Telix Innovations projects
8 ClinicalTrials.gov programs sponsored by Telix Innovations.
Telix Innovations has 8 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
177Lu girentuximab
Telix Innovations
Advanced Cancer
1 trial -
177Lu-DOTA-TLX591
Telix Innovations
Prostate Cancer
1 trial -
4-L-[131I]iodo-phenylalanine (131I-IPA)
Telix Innovations
Glioblastoma Multiforme
1 trial -
89Zr-Girentuximab
Telix Innovations
Clear Cell Renal Cell Carcinoma (ccRCC)
1 trial -
89Zr-girentuximab for PET/CT imaging of CAIX positive tumors
Telix Innovations
Cervical Cancer
1 trial -
Fluciclovine F18
Telix Innovations
Prostate Adenocarcinoma
1 trial -
PSMA PET/MR - Gallium-68 labeled PSMA-HBED-CC
Telix Innovations
Prostate Cancer
1 trial -
Zirconium Zr 89 Girentuximab
Telix Innovations
Clear Cell Renal Cell Carcinoma
1 trial
Frequently asked questions
How many clinical projects does Telix Innovations have?
8 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.